Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Hepatology (Baltimore, Md.)
|
July 19, 2024
Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
Daniel Q Huang, Laura A Wilson, Cynthia Behling, et al.
The New England Journal of Medicine
|
June 10, 2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L Hartman, Eric J Lawitz, et al.
Gastroenterology
|
April 17, 2018
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Veeral Ajmera, Charlie C Park, Cyrielle Caussy, et al.
Hepatology (Baltimore, Md.)
|
October 23, 2023
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease
Andrew Wang, Amanda L Blackford, Cynthia Behling, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
December 12, 2025
Vibration-controlled transient elastography in pediatric metabolic dysfunction-associated steatotic liver disease
Lauren B Nichols, Sebastian G J Oakes, Cynthia Behling, et al.
Journal of Hepatology
|
October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
Alimentary Pharmacology & Therapeutics
|
June 3, 2023
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD
Beom K Kim, Nicole Bernstein, Daniel Q Huang, et al.
Lancet (London, England)
|
August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Mazen Noureddin, Juan P Frias, Guy W Neff, et al.
Alimentary Pharmacology & Therapeutics
|
October 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum
Melissa Palmer, David E Kleiner, Zachary Goodman, et al.
Alimentary Pharmacology & Therapeutics
|
March 22, 2024
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease
Rohit Loomba, Ginger Clark, Jeff Teckman, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Hepatology (Baltimore, Md.)
|
July 19, 2024
Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
Daniel Q Huang, Laura A Wilson, Cynthia Behling, et al.
The New England Journal of Medicine
|
June 10, 2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L Hartman, Eric J Lawitz, et al.
Gastroenterology
|
April 17, 2018
Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Veeral Ajmera, Charlie C Park, Cyrielle Caussy, et al.
Hepatology (Baltimore, Md.)
|
October 23, 2023
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease
Andrew Wang, Amanda L Blackford, Cynthia Behling, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
December 12, 2025
Vibration-controlled transient elastography in pediatric metabolic dysfunction-associated steatotic liver disease
Lauren B Nichols, Sebastian G J Oakes, Cynthia Behling, et al.
Journal of Hepatology
|
October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
Alimentary Pharmacology & Therapeutics
|
June 3, 2023
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD
Beom K Kim, Nicole Bernstein, Daniel Q Huang, et al.
Lancet (London, England)
|
August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Mazen Noureddin, Juan P Frias, Guy W Neff, et al.
Alimentary Pharmacology & Therapeutics
|
October 25, 2023
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum
Melissa Palmer, David E Kleiner, Zachary Goodman, et al.
Alimentary Pharmacology & Therapeutics
|
March 22, 2024
Review article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease
Rohit Loomba, Ginger Clark, Jeff Teckman, et al.
Page
of 9